Nrf1 and Nrf2 transcription factors regulate androgen receptor transactivation in prostate cancer cells

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Schultz, Michelle A ^a,c   Hagan, Sharika S ^a   Datta, Amrita ^a   Zhang, Yiguo ^b   Freeman, Michael L ^c   Sikka, Suresh C ^a   Abdel Mageed, Asim B ^a   Mondal, Debasis ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CHONGQING UNIVERSITY   (China)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANDROSTANOLONE; DNA; PROTEIN P120; SMALL INTERFERING RNA; SYNAPTOTAGMIN I; TRANSCRIPTION FACTOR NRF1; TRANSCRIPTION FACTOR NRF2;

ARTICLE; BIOACCUMULATION; CANCER CELL; CANCER CELL LINE; CONTROLLED STUDY; DRUG EFFECT; GENE OVEREXPRESSION; GENE SILENCING; HORMONE RESPONSIVE ELEMENT; IN VITRO STUDY; PROSTATE CANCER; PROTEIN DNA BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; TRANSACTIVATION;

ANALYSIS OF VARIANCE; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; DIHYDROTESTOSTERONE; DNA PRIMERS; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HUMANS; IMMUNOBLOTTING; LUCIFERASES; MALE; NF-E2-RELATED FACTOR 2; NUCLEAR RESPIRATORY FACTOR 1; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; TRANSCRIPTIONAL ACTIVATION;

EID: 84899525548     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087204     Document Type: Article

References (51)

1. American Cancer Society. Cancer Facts & Figures 2012. Atlanta: American Cancer Society.
2. McPhaul MJ. (2008). Mechanisms of prostate cancer progression to androgen independence. Best Pract Res Clin Endocrinol Metab. 22: 373-388.
3. Nadiminty N, Gao AC (2012). Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives. World J Urol. 30: 287-295.
4. Vis AN, Schroder FH (2009). Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways. BJU Int. 104: 438-448.
5. Yamaoka M, Hara T, Kusaka M (2010). Overcoming persistent dependency on androgen signaling after progression to castration-resistant prostate cancer. Clin Cancer Res. 16: 4319-4324.
6. Shiota M, Yokomizo A, Tada Y, Inokuchi J, Kashiwagi E, et al. (2010). Castration resistance of prostate cancer cells caused by castration-induced oxidative stress through Twist1 and androgen receptor overexpression. Oncogene. 29: 237-250.
7. Locke JA, Guns ES, Lubik AA, Adomat HH, Hendy SC, et al. (2008). Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 68: 6407-6415.
8. Mehraein-Ghomi F, Basu HS, Church DR, Hoffmann FM, Wilding G (2010). Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. Cancer Res. 70: 4560-4568.
9. Culig Z, Santer FR (2012). Androgen receptor co-activators in the regulation of cellular events in prostate cancer. World J Urol. 30: 297-302.
10. Shiota M, Song Y, Takeuchi A, Yokomizo A, Kashiwagi E, et al. (2012). Antioxidant therapy alleviates oxidative stress by androgen deprivation and prevents conversion from androgen dependent to castration resistant prostate cancer. J Urol. 187: 707-714.
11. Khandrika L, Kumar B, Koul S, Maroni P, Koul HK (2009). Oxidative stress in prostate cancer. Cancer Lett. 282: 125-136.
12. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK (2008). Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res. 68: 1777-1785. (Pubitemid 351416563)
13. Yossepowitch O, Pinchuk I, Gur U, Neumann A, Lichtenberg D, et al. (2007). Advanced but not localized prostate cancer is associated with increased oxidative stress. J Urol. 178: 1238-1243; discussion 1243-1234.
14. Chhipa RR, Lee KS, Onate S, Wu Y, Ip C (2009). Prx1 enhances androgen receptor function in prostate cancer cells by increasing receptor affinity to dihydrotestosterone. Mol Cancer Res. 7: 1543-1552.
15. Park SY, Yu X, Ip C, Mohler JL, Bogner PN, et al. (2007). Peroxiredoxin 1 interacts with androgen receptor and enhances its transactivation. Cancer Res. 67: 9294-9303. (Pubitemid 47535918)
16. Tam NN, Gao Y, Leung YK, Ho SM (2003). Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol. 163: 2513-2522. (Pubitemid 37466492)
17. Lu JP, Monardo L, Bryskin I, Hou ZF, Trachtenberg J, et al. (2010). Androgens induce oxidative stress and radiation resistance in prostate cancer cells though NADPH oxidase. Prostate Cancer Prostatic Dis. 13: 39-46.
18. Ohtsuji M, Katsuoka F, Kobayashi A, Aburatani H, Hayes JD, et al. (2008). Nrf1 and Nrf2 play distinct roles in activation of antioxidant response element-dependent genes. J Biol Chem. 283: 33554-33562.
19. Pendyala S, Natarajan V (2010). Redox regulation of Nox proteins. Respir Physiol Neurobiol. 174: 265-271.
20. Reisman SA, Yeager RL, Yamamoto M, Klaassen CD (2009). Increased Nrf2 activation in livers from Keap1-knockdown mice increases expression of cytoprotective genes that detoxify electrophiles more than those that detoxify reactive oxygen species. Toxicol Sci. 108: 35-47.
21. Gamcsik MP, Kasibhatla MS, Teeter SD, Colvin OM (2012). Glutathione levels in human tumors. Biomarkers. 8: 671-691.
22. Han W, Ming M, Zhao R, Pi J, Wu C, et al. (2012). Nrf1 CNC-bZIP protein promotes cell survival and nucleotide excision repair through maintaining glutathione homeostasis. J Biol Chem. 287: 18788-18795.
23. Lu W, Hu Y, Chen G, Chen Z, Zhang H, et al. (2012). Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy. PLoS Biol. 10: e1001326.
24. Friling RS, Bensimon A, Tichauer Y, Daniel V (1990). Xenobiotic-inducible expression of murine glutathione S-transferase Ya subunit gene is controlled by an electrophile-responsive element. Proc Natl Acad Sci U S A. 87: 6258-6262.
25. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD (2008). Dual roles of Nrf2 in cancer. Pharmacol Res. 58: 262-270.
26. Itoh K, Tong KI, Yamamoto M (2004). Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles. Free Radic Biol Med. 36: 1208-1213. (Pubitemid 38526314)
27. Wang W, Chan JY (2006). Nrf1 is targeted to the endoplasmic reticulum membrane by an N-terminal transmembrane domain. Inhibition of nuclear translocation and transacting function. J Biol Chem. 281: 19676-19687. (Pubitemid 44035470)
28. Zhang Y, Lucocq JM, Hayes JD (2009). The Nrf1 CNC/bZIP protein is a nuclear envelope-bound transcription factor that is activated by t-butyl hydroquinone but not by endoplasmic reticulum stressors. Biochem J. 418: 293-310.
29. Johnsen O, Murphy P, Prydz H, Kolsto AB (1998). Interaction of the CNCbZIP factor TCF11/LCR-F1/Nrf1 with MafG: binding-site selection and regulation of transcription. Nucleic Acids Res. 26: 512-520. (Pubitemid 28291577)
30. Wang W, Kwok AM, Chan JY (2007). The p65 isoform of Nrf1 is a dominant negative inhibitor of ARE-mediated transcription. J Biol Chem. 282: 24670-24678. (Pubitemid 47347500)
31. Zhang Y, Hayes JD (2013). The membrane-topogenic vectorial behaviour of Nrf1 controls its post-translational modification and transactivation activity. Sci Rep. 3:2006. doi: 10.1038/srep02006.
32. Yu S, Khor TO, Cheung KL, Li W, Wu TY, et al. (2010). Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice. PLoS One. 5: e8579.
33. Frohlich DA, McCabe MT, Arnold RS, Day ML (2008). The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene. 27: 4353-4362. (Pubitemid 352010007)
34. Huang Y, Khor TO, Shu L, Saw CL, Wu TY, et al. (2012). A gamma-tocopherol-rich mixture of tocopherols maintains Nrf2 expression in prostate tumors of TRAMP mice via epigenetic inhibition of CpG methylation. J Nutr. 142: 818-823.
35. Chepelev NL, Bennitz JD, Huang T, McBride S, Willmore WG (2011). The Nrf1 CNC-bZIP protein is regulated by the proteasome and activated by hypoxia. PLoS One. 6: e29167.
36. Schultz MA, Abdel-Mageed AB, Mondal D (2010). The Nrf1 and Nrf2 Balance in Oxidative Stress Regulation and Androgen Signaling in Prostate Cancer Cells. Cancers. 2: 1354-1378.
37. Chen ME, Lin SH, Chung LW, Sikes RA (1998). Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem. 273: 17618-17625. (Pubitemid 28355099)
38. Zhang Y, Crouch DH, Yamamoto M, Hayes JD (2006). Negative regulation of the Nrf1 transcription factor by its N-terminal domain is independent of Keap1: Nrf1, but not Nrf2, is targeted to the endoplasmic reticulum. Biochem J. 399: 373-385. (Pubitemid 44672628)
39. Davis R, Jia D, Cinar B, Sikka SC, Moparty K, et al. (2003). Functional androgen receptor confers sensitization of androgen-independent prostate cancer cells to anticancer therapy via caspase activation. Biochem Biophys Res Commun. 309: 937-945. (Pubitemid 37122620)
40. Lee S, Lim MJ, Kim MH, Yu CH, Yun YS, et al. (2012). An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med. 53: 807-816.
41. Cheung KL, Lee JH, Khor TO, Wu TY, Li GX, et al. (2014). Nrf2 knockout enhances intestinal tumorigenesis in Apc(min/+) mice due to attenuation of anti-oxidative stress pathway while potentiates inflammation. Mol Carcinog. 53: 77-84.
42. Sykiotis GP, Bohmann D (2010). Stress-activated cap'n'collar transcription factors in aging and human disease. Sci Signal. 3: re3. doi:10.1126/scisignal.3112re3.
43. Lin HK, Altuwaijri S, Lin WJ, Kan PY, Collins LL, et al. (2002). Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J Biol Chem. 277: 36570-36576.
44. Yang H, Chen D, Cui QC, Yuan X, Dou QP (2006). Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res. 66: 4758-4765.
45. Husberg C, Murphy P, Bjorgo E, Kalland KH, Kolsto AB (2003). Cellular localisation and nuclear export of the human bZIP transcription factor TCF11. Biochim Biophys Acta. 1640: 143-151. (Pubitemid 36555700)
46. Steffen J, Seeger M, Koch A, Kruger E (2010). Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell. 40: 147-158.
47. Tsujimoto Y, Tomita Y, Hoshida Y, Kono T, Oka T, et al. (2004). Elevated expression of valosin-containing protein (p97) is associated with poor prognosis of prostate cancer. Clin Cancer Res. 10: 3007-3012. (Pubitemid 38619676)
48. Chou TF, Brown SJ, Minond D, Nordin BE, Li K, et al. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc Natl Acad Sci U S A. 108: 4834-4839.
49. Nair S, Barve A, Khor TO, Shen GX, Lin W, et al. (2010). Regulation of Nrf2-and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. Acta Pharmacol Sin. 31: 1223-1240.
50. Keum YS, Khor TO, Lin W, Shen G, Kwon KH, et al. (2009). Pharmacokinetics and pharmacodynamics of broccoli sprouts on the suppression of prostate cancer in transgenic adenocarcinoma of mouse prostate (TRAMP) mice: implication of induction of Nrf2, HO-1 and apoptosis and the suppression of Akt-dependent kinase pathway. Pharm Res. 26: 2324-2331.
51. Fajardo AM, MacKenzie DA, Ji M, Deck LM, Vander Jagt DL, et al. (2011). The curcumin analog ca27 down-regulates androgen receptor through an oxidative stress mediated mechanism in human prostate cancer cells. Prostate. 72: 612-625.